Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Pediatric Hematology-Oncology

Building Your Care Team and Protecting Your Family

At a Glance

Treating Familial Hemophagocytic Lymphohistiocytosis (FHL) requires a multidisciplinary medical team led by a pediatric hematologist-oncologist and transplant specialist. Immediate genetic testing for siblings is critical, as preemptive stem cell transplants can cure them before symptoms appear.

Managing Familial Hemophagocytic Lymphohistiocytosis (FHL) is too complex for any one doctor. Because this condition can affect the blood, brain, liver, and immune system, you will need a multidisciplinary team of specialists working in tight coordination [1][2].

Your Core Medical Team

Your child’s care will likely be led by a pediatric hematologist-oncologist, but several other experts are essential:

  • Pediatric Hematologist-Oncologist: This doctor manages the day-to-day treatment, including the chemotherapy (such as etoposide and dexamethasone) used to stabilize the immune system [3][4].
  • Bone Marrow Transplant (BMT) Specialist: Since hematopoietic stem cell transplant (HSCT) is the only cure, this specialist should be involved early to begin the search for a donor and plan the curative phase [4][5].
  • Infectious Disease (ID) Specialist: FHL itself—and the chemotherapy used to treat it—severely weakens the immune system. An ID doctor is critical for preventing and managing life-threatening bacterial, viral, and fungal infections during treatment [6][7].
  • Immunologist: An expert in the immune system who can help interpret complex functional tests (like NK cell activity) and genetic results [8].
  • Neurologist: Because FHL frequently affects the central nervous system (CNS), a neurologist is needed to monitor brain health using MRIs and physical exams [9][10].

Protecting the Family: Sibling Screening

FHL is an autosomal recessive disorder, meaning a child must inherit one mutated gene from each parent to be affected [11]. This has critical implications for your other children:

  • Immediate Genetic Testing: It is strongly recommended that all siblings of a child with FHL be tested for the family’s specific genetic mutation, even if they appear perfectly healthy [12][13].
  • Preemptive Transplant: If a sibling is found to have the same biallelic mutations (two “broken” copies of the gene) but has not yet shown symptoms, doctors may recommend a preemptive HSCT [12][14]. Research shows that performing the transplant while a child is healthy—before a “cytokine storm” ever begins—is a safe and effective way to prevent the disease from ever starting and leads to better overall outcomes [14][15][13].

Vetting Your Care Team

FHL is a rare “orphan” disease. When you meet with a specialist, it is important to ensure they have the specific expertise required for primary HLH. You may wish to ask:

  1. “How many children with primary FHL have you personally treated?” (Experience with secondary HLH is common; experience with the genetic form is rarer).
  2. “Is your center a member of the Histiocyte Society or a participant in HLH clinical trials?” [16].
  3. “What is your protocol for coordinating care between the hematology, infectious disease, and transplant teams?”

A high-volume center that specializes in rare immune disorders will often have the best resources to manage the high stakes of FHL care [8][17].

Common questions in this guide

Which doctors should be on my child's FHL care team?
Your child's care should be led by a pediatric hematologist-oncologist and a bone marrow transplant specialist. The team must also include an infectious disease expert, an immunologist, and a neurologist to manage the complex effects of FHL on the body and brain.
Should my other children be tested for FHL?
Yes, it is strongly recommended that all siblings be tested for the family's specific genetic mutation, even if they appear perfectly healthy. Because FHL is a genetic disorder, siblings have a significant risk of having the same condition.
What happens if a healthy sibling tests positive for FHL?
If a sibling has the same genetic mutations but no symptoms, doctors often recommend a preemptive stem cell transplant. Performing the transplant while the child is still healthy can prevent the disease from ever starting and typically leads to much better outcomes.
How do I find the right hospital for FHL treatment?
Look for a high-volume center that specializes in rare immune disorders and has specific experience treating primary (genetic) FHL. It is highly beneficial if the center is a member of the Histiocyte Society or actively participates in HLH clinical trials.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many children with primary (familial) HLH has this center treated in the last five years?
  2. 2.Does your transplant team have specific experience with FHL, and what are the survival rates for this specific condition at your hospital?
  3. 3.Will our care be coordinated through a multidisciplinary team that includes an immunologist, an infectious disease specialist, and a neurologist?
  4. 4.How quickly can we begin genetic testing for my other children?
  5. 5.Are you currently following the HLH-94 or HLH-2004 protocol, and how will you decide when my child is ready for transplant?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults.

    Hines MR, von Bahr Greenwood T, Beutel G, et al.

    Critical care medicine 2022; (50(5)):860-872 doi:10.1097/CCM.0000000000005361.

    PMID: 34605776
  2. 2

    Neurological Abnormality Could be the First and Only Symptom of Familial Hemophagocytic Lymphohistiocytosis: Report of Two Families.

    Zhao YZ, Cheng H, Ding CH, et al.

    Chinese medical journal 2018; (131(24)):3004-3006 doi:10.4103/0366-6999.247206.

    PMID: 30539918
  3. 3

    The Safety and Efficacy of Ruxolitinib in an Infant With Familial Hemophagocytic Syndrome Type 3: A Bridging Therapy Toward Hematopoietic Cell Transplantation and Treatment of Post-Transplant Complications, Including Sinusoidal Obstruction Syndrome.

    Takahashi K, Hirabayashi S, Ueki M, et al.

    Pediatric blood & cancer 2025; (72(12)):e32073 doi:10.1002/pbc.32073.

    PMID: 40993979
  4. 4

    Clinical, Genetic, and Outcome Characteristics of Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis.

    Nepesov S, Yaman Y, Elli M, et al.

    Turkish archives of pediatrics 2022; (57(4)):398-405 doi:10.5152/TurkArchPediatr.2022.21314.

    PMID: 35822471
  5. 5

    Familial Hemophagocytic Lymphohistiocytosis.

    Degar B

    Hematology/oncology clinics of North America 2015; (29(5)):903-13.

    PMID: 26461150
  6. 6

    Efficacy and safety of ruxolitinib-based regimen in the treatment of paediatric Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.

    Wang W, Zhao Y, Ge J, et al.

    British journal of haematology 2025; (207(3)):902-910 doi:10.1111/bjh.20264.

    PMID: 40665481
  7. 7

    Hemophagocytic Lymphohistiocytosis and Graft Failure Following Unrelated Umbilical Cord Blood Transplantation in Children.

    Noguchi M, Inagaki J

    Journal of pediatric hematology/oncology 2020; (42(6)):e440-e444 doi:10.1097/MPH.0000000000001795.

    PMID: 32287100
  8. 8

    Diagnostic guidelines for familial hemophagocytic lymphohistiocytosis revisited.

    Henter JI, Sieni E, Eriksson J, et al.

    Blood 2024; (144(22)):2308-2318 doi:10.1182/blood.2024025077.

    PMID: 39046779
  9. 9

    Clinical and neuroimaging features of familial hemophagocytic lymphohistiocytosis.

    Alkaphoury MG, Mohammad SA, Farghal NBE, et al.

    Pediatric radiology 2026; (56(2)):443-454 doi:10.1007/s00247-025-06454-5.

    PMID: 41251694
  10. 10

    Isolated Central Nervous System FHL3 in an Asian Pediatric Patient: A Case Report and Literature Review.

    Zhang Z, Duan H, Zhang C, et al.

    Journal of inflammation research 2025; (18()):13625-13633 doi:10.2147/JIR.S543598.

    PMID: 41064495
  11. 11

    Clinical, immunological and genetic findings in patients with UNC13D deficiency (FHL3): A systematic review.

    Amirifar P, Ranjouri MR, Abolhassani H, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2021; (32(1)):186-197 doi:10.1111/pai.13323.

    PMID: 32679608
  12. 12

    Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis.

    Lucchini G, Marsh R, Gilmour K, et al.

    Blood 2018; (132(19)):2088-2096 doi:10.1182/blood-2018-01-827485.

    PMID: 30104219
  13. 13

    Case report: Cerebellar swelling and hydrocephalus in familial hemophagocytic lymphohistiocytosis.

    Yoshida T, Moriya K, Oikawa K, et al.

    Frontiers in pediatrics 2022; (10()):1051623 doi:10.3389/fped.2022.1051623.

    PMID: 36589154
  14. 14

    Successful correction of familial hemophagocytic lymphohistiocytosis using prenatal genetic testing and preemptive hematopoietic stem cell transplantation.

    Michniacki TF, Mulcahy Levy JM, Quinones RR, Giller RH

    Bone marrow transplantation 2018; (53(2)):223-224 doi:10.1038/bmt.2017.219.

    PMID: 29035396
  15. 15

    Familial hemophagocytic lymphohistiocytosis in a girl with a novel homozygous mutation of STX11: A case report.

    Guo X, Jiang M, Tang X, Li Q

    Medicine 2019; (98(48)):e18107 doi:10.1097/MD.0000000000018107.

    PMID: 31770233
  16. 16

    Histiocyte Society blueprint for hemophagocytic lymphohistiocytosis research: deciphering underlying disease mechanisms to optimize diagnosis and therapy.

    Meyer LK, Lee JC, Rocco JM, Nichols KE

    Haematologica 2025; (110(11)):2572-2587 doi:10.3324/haematol.2024.286477.

    PMID: 41178437
  17. 17

    Familial Hemophagocytic Lymphohistiocytosis Type 2 in a Chinese Infant with PRF1 Homozygous Mutation: a Case Report.

    Ji Q, Wang G, Xu W

    Clinical laboratory 2020; (66(7)) doi:10.7754/Clin.Lab.2019.191136.

    PMID: 32658436

This page is for informational purposes only and does not replace professional medical advice. Always consult your child's pediatric hematologist-oncologist and transplant team about specific treatment plans and sibling screening.

Get notified when new evidence is published on Familial hemophagocytic lymphohistiocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.